Bisharah Rizvi

Bisharah Rizvi

Auto-generated profile, based on publicly available information

Bisharah Rizvi

Department of Pulmonary and Critical Care Medicine, United Health Services Southern California Medical Education Consortium, Temecula, CA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Mediastinum
Verified
Journal Article
Open access
PDF file
BRBisharah Rizvi
Bisharah Rizvi
JPJorge A. Munoz Pineda
Jorge A. Munoz Pineda
KNKeriann Van Nostrand
Keriann Van Nostrand
Russell MillerRussell Miller
Russell Miller
George Z ChengGeorge Z Cheng
George Z Cheng
NPNiral M. Patel
Niral M. Patel
Background and Objective: Linear endobronchial ultrasound (EBUS) has become a key tool for diagnosing pulmonary diseases, offering high diagnostic yield for both malignant and non-malignant conditions. With its increased use, more complications are being reported. The objective of this narrative review is to discuss the complications associated with linear EBUS. Methods: A literature search using PubMed and Google Scholar from 2009 to 2024 was done. We included case reports, prospective, and retrospective studies reporting linear EBUS complications. Key Content and Findings: Overall complications from EBUS range from 0.04% to 17%. Most common are infectious complications which are 0.04–4%. These include mediastinitis, pneumonia, pericarditis, bacteremia, tumor bed infection, lung abscess, empyema, and septic shock. Other complications include pneumothorax, pneumomediastinum, pneumopericardium, pneumoperitoneum, and subcutaneous emphysema. Complications due to anesthesia or equipment malfunction can occur as well. Hemorrhagic complications have been reported as well. Mortality is low 0.01–0.04%, and four cases have been reported that led to death from complications. Conclusions: With increased use of EBUS as a diagnostic tool, number of complications will increase. Clinicians performing the procedures should be aware of types of possible complications that can occur and follow the patients closely after the procedure. Rapid diagnosis and treatment should be done to avoid fatal outcomes.

28 January 2025 in Thoracic Research and Practice
Verified
Journal Article
Open access
RDRupak Desai
Rupak Desai
SSSashwath Srikanth
Sashwath Srikanth
SCShaylika Chauhan
Shaylika Chauhan
ZGZainab Gandhi
Zainab Gandhi
WSWarda Shahnawaz
Warda Shahnawaz
AJAkhil Jain
Akhil Jain
Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations - Thoracic Research and Practice

28 November 2023 in EXCLI Journal
Verified
Journal Article
Open access
RDRupak Desai
Rupak Desai
ZGZainab Gandhi
Zainab Gandhi
SSSaher Taj Shiza
Saher Taj Shiza
AJAkhil Jain
Akhil Jain
HKHiren Koshiya
Hiren Koshiya
Salim SuraniSalim Surani
Salim Surani
Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results.